Brand Intelligence Graph
Company Overview
About Life Biosciences
Life Biosciences is running the first FDA-cleared human trial of partial epigenetic reprogramming, using gene therapy to reverse vision loss caused by aging. Co-founded by Harvard aging biologist David Sinclair — whose research showed that aged retinal cells could be restored to youthful function by expressing Yamanaka factors — Life Biosciences received FDA clearance for its IND (Investigational New Drug) for ER-100 in optic neuropathies in January 2026 and closed an $80 million Series D in April 2026.
Business Model & Competitive Advantage
The optic neuropathy indication is a smart clinical strategy: the eye is an immune-privileged site that allows targeted gene therapy delivery with minimal systemic risk, enabling safety data to be collected in a setting where the target tissue and disease are well-characterized. Positive safety and efficacy data in the eye would establish proof-of-concept for epigenetic reprogramming in vivo, enabling the approach to be extended to systemic aging across other tissues.
Competitive Landscape 2025–2026
The $80 million Series D provides runway through trial completion and positions Life Biosciences as the first company to generate human clinical data on whether the epigenetic clock of aging can be reversed — a question with transformative implications for medicine if the answer is yes.
Key Differentiators
Emerging Innovator
Life Biosciences is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Life Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Life Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Life Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Life Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →